Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 24 | 2023 | 281 | 3.660 |
Why?
|
| Brain | 19 | 2023 | 1268 | 2.200 |
Why?
|
| Neuroglia | 3 | 2016 | 117 | 1.230 |
Why?
|
| HIV Infections | 13 | 2023 | 2207 | 1.140 |
Why?
|
| Glutamic Acid | 6 | 2009 | 115 | 1.130 |
Why?
|
| Brain Chemistry | 5 | 2013 | 134 | 0.980 |
Why?
|
| Anti-HIV Agents | 3 | 2016 | 394 | 0.850 |
Why?
|
| gamma-Aminobutyric Acid | 6 | 2023 | 70 | 0.840 |
Why?
|
| Frontal Lobe | 3 | 2010 | 49 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 468 | 0.710 |
Why?
|
| Bicarbonates | 3 | 2013 | 12 | 0.660 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 219 | 0.610 |
Why?
|
| DNA, Viral | 3 | 2013 | 295 | 0.610 |
Why?
|
| Carbon Isotopes | 5 | 2013 | 38 | 0.600 |
Why?
|
| Glutathione | 4 | 2018 | 160 | 0.590 |
Why?
|
| Adult | 28 | 2023 | 11034 | 0.530 |
Why?
|
| Acetates | 2 | 2010 | 20 | 0.480 |
Why?
|
| Psychotic Disorders | 3 | 2019 | 52 | 0.470 |
Why?
|
| Acid-Base Equilibrium | 1 | 2013 | 7 | 0.470 |
Why?
|
| Fasting | 1 | 2013 | 50 | 0.460 |
Why?
|
| Male | 34 | 2023 | 18870 | 0.460 |
Why?
|
| Neurons | 3 | 2016 | 1130 | 0.460 |
Why?
|
| Cerebellum | 1 | 2013 | 69 | 0.450 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 182 | 0.410 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 274 | 0.400 |
Why?
|
| Humans | 39 | 2023 | 34853 | 0.390 |
Why?
|
| Female | 28 | 2020 | 19873 | 0.390 |
Why?
|
| Schizophrenia | 2 | 2022 | 73 | 0.370 |
Why?
|
| Drug Discovery | 1 | 2011 | 77 | 0.370 |
Why?
|
| Drug Users | 1 | 2009 | 42 | 0.350 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2009 | 63 | 0.350 |
Why?
|
| Aspartic Acid | 6 | 2016 | 46 | 0.340 |
Why?
|
| Receptors, GABA | 2 | 2019 | 22 | 0.330 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 139 | 0.330 |
Why?
|
| Young Adult | 14 | 2023 | 4012 | 0.320 |
Why?
|
| Methamphetamine | 1 | 2009 | 155 | 0.320 |
Why?
|
| Prefrontal Cortex | 2 | 2019 | 133 | 0.300 |
Why?
|
| Central Nervous System | 3 | 2021 | 130 | 0.290 |
Why?
|
| Middle Aged | 14 | 2023 | 9642 | 0.290 |
Why?
|
| Mental Disorders | 1 | 2008 | 285 | 0.260 |
Why?
|
| Clozapine | 1 | 2022 | 17 | 0.220 |
Why?
|
| Cognition Disorders | 2 | 2016 | 233 | 0.220 |
Why?
|
| Water | 3 | 2019 | 283 | 0.210 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 79 | 0.210 |
Why?
|
| Choline | 5 | 2016 | 57 | 0.200 |
Why?
|
| Image Enhancement | 3 | 2012 | 41 | 0.190 |
Why?
|
| Tissue Distribution | 3 | 2017 | 197 | 0.170 |
Why?
|
| Commerce | 1 | 2020 | 81 | 0.170 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 901 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2013 | 628 | 0.170 |
Why?
|
| Reference Values | 3 | 2019 | 204 | 0.170 |
Why?
|
| Creatine | 5 | 2010 | 8 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 21 | 0.170 |
Why?
|
| Heroin | 1 | 2018 | 11 | 0.170 |
Why?
|
| RNA, Viral | 2 | 2017 | 287 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2018 | 116 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 135 | 0.160 |
Why?
|
| Glutathione Peroxidase | 1 | 2018 | 109 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 6 | 0.150 |
Why?
|
| Acute Disease | 3 | 2012 | 141 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2018 | 104 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2017 | 30 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 222 | 0.150 |
Why?
|
| Antioxidants | 2 | 2018 | 386 | 0.140 |
Why?
|
| Seals, Earless | 2 | 2008 | 6 | 0.140 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2015 | 7 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 105 | 0.140 |
Why?
|
| Cocaine | 1 | 2018 | 219 | 0.140 |
Why?
|
| Receptors, CCR5 | 1 | 2015 | 59 | 0.140 |
Why?
|
| Neurofilament Proteins | 1 | 2015 | 27 | 0.130 |
Why?
|
| HIV | 3 | 2023 | 97 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2561 | 0.120 |
Why?
|
| Oxidation-Reduction | 2 | 2018 | 407 | 0.120 |
Why?
|
| Risk | 3 | 2019 | 256 | 0.120 |
Why?
|
| Phosphorus Isotopes | 1 | 2013 | 8 | 0.120 |
Why?
|
| Atrophy | 1 | 2013 | 40 | 0.120 |
Why?
|
| Quality Control | 1 | 2012 | 35 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 11 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 555 | 0.110 |
Why?
|
| Inositol | 4 | 2005 | 20 | 0.110 |
Why?
|
| Central Nervous System Infections | 1 | 2012 | 4 | 0.110 |
Why?
|
| Succinates | 1 | 2011 | 3 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 342 | 0.110 |
Why?
|
| Citric Acid Cycle | 1 | 2011 | 4 | 0.110 |
Why?
|
| Arteries | 1 | 2012 | 67 | 0.110 |
Why?
|
| Contrast Media | 1 | 2012 | 95 | 0.110 |
Why?
|
| Glucose | 2 | 2010 | 217 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2009 | 1056 | 0.100 |
Why?
|
| Depression | 1 | 2017 | 664 | 0.100 |
Why?
|
| Adolescent | 5 | 2023 | 5035 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 639 | 0.100 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 11 | 0.100 |
Why?
|
| Phosphocreatine | 1 | 2010 | 10 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 65 | 0.100 |
Why?
|
| Anxiety | 1 | 2017 | 705 | 0.100 |
Why?
|
| Metabolomics | 1 | 2011 | 76 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 98 | 0.090 |
Why?
|
| Myoglobin | 3 | 2008 | 8 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2020 | 1353 | 0.090 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2009 | 1 | 0.090 |
Why?
|
| Thailand | 2 | 2020 | 48 | 0.090 |
Why?
|
| Kinetics | 1 | 2010 | 650 | 0.090 |
Why?
|
| Cell Respiration | 2 | 2008 | 33 | 0.090 |
Why?
|
| Anilides | 2 | 2019 | 27 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2008 | 23 | 0.080 |
Why?
|
| Muscles | 1 | 2008 | 64 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2007 | 528 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2012 | 1349 | 0.080 |
Why?
|
| Viral Load | 2 | 2021 | 300 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 66 | 0.080 |
Why?
|
| Pyridines | 2 | 2019 | 113 | 0.080 |
Why?
|
| Inflammation | 1 | 2012 | 577 | 0.080 |
Why?
|
| Autopsy | 2 | 2018 | 40 | 0.080 |
Why?
|
| Phantoms, Imaging | 4 | 2010 | 22 | 0.070 |
Why?
|
| Protons | 2 | 2004 | 80 | 0.070 |
Why?
|
| Decision Making | 1 | 2008 | 189 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2005 | 43 | 0.060 |
Why?
|
| Lactates | 1 | 2004 | 8 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2004 | 63 | 0.060 |
Why?
|
| Age Factors | 1 | 2007 | 1007 | 0.060 |
Why?
|
| Sex Factors | 1 | 2007 | 859 | 0.060 |
Why?
|
| Animals | 5 | 2012 | 14307 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2004 | 160 | 0.060 |
Why?
|
| Aged | 3 | 2016 | 6448 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 257 | 0.050 |
Why?
|
| Apnea | 1 | 2002 | 6 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 18 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2018 | 874 | 0.050 |
Why?
|
| Oxygen | 3 | 2008 | 193 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 148 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 138 | 0.040 |
Why?
|
| Heroin Dependence | 1 | 2018 | 23 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 55 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 881 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 84 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 185 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 92 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 2333 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 217 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2006 | 59 | 0.030 |
Why?
|
| Algorithms | 2 | 2010 | 435 | 0.030 |
Why?
|
| Dipeptides | 2 | 2004 | 29 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 871 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 63 | 0.030 |
Why?
|
| Static Electricity | 1 | 2012 | 75 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 1014 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 429 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2012 | 202 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2012 | 196 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2011 | 51 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 179 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1318 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 570 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 67 | 0.030 |
Why?
|
| Monocytes | 1 | 2013 | 258 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1422 | 0.020 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 8 | 0.020 |
Why?
|
| Microwaves | 1 | 2010 | 26 | 0.020 |
Why?
|
| Free Radicals | 1 | 2010 | 72 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 649 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 164 | 0.020 |
Why?
|
| Polyphosphates | 1 | 2008 | 3 | 0.020 |
Why?
|
| Neurochemistry | 1 | 2008 | 6 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 86 | 0.020 |
Why?
|
| Child | 1 | 2016 | 2875 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 406 | 0.020 |
Why?
|
| Temperature | 1 | 2008 | 275 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 1961 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3414 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3261 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2004 | 17 | 0.020 |
Why?
|
| Phosphates | 1 | 2004 | 49 | 0.020 |
Why?
|
| Radio Waves | 1 | 2004 | 4 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 211 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2004 | 78 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2004 | 40 | 0.020 |
Why?
|
| Hydrogen | 1 | 2004 | 47 | 0.020 |
Why?
|
| Glutamine | 1 | 2004 | 31 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 180 | 0.010 |
Why?
|
| Neuropeptides | 1 | 2004 | 57 | 0.010 |
Why?
|
| Diving | 1 | 2002 | 2 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 2002 | 5 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 469 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 5668 | 0.010 |
Why?
|